BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma

G. Talamo, D. F. Claxton, D. W. Dougherty, C. W. Ehmann, J. Sivik, J. J. Drabick, W. Rybka

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


High-dose melphalan is considered the current standard of care among the preparative regimens used in peripheral blood autologous SCT (ASCT) for multiple myeloma (MM). We report the results of a single ASCT in 79 MM patients using the BU/CY conditioning regimen, with BU 1mg/kg p.o. or 0.8mg/kg i.v. every 6h × 16 doses, and CY 60mg/kg per day i.v. for 2 days. ASCT was carried out in first (62%) or subsequent remission/ refractory disease (38%). For an overall RR of 86%, 48 and 20 patients achieved PR and CR, respectively. At a median follow-up of 41 months (range 2-132 months), the estimated median OS and PFS were 45 months (95% confidence interval (CI) = 38-92) and 20 months (95% CI = 15-25), respectively. The BU/CY regimen was well tolerated, and transplant-related mortality was 4%. Clinical outcomes of the BU/CY regimen are not superior to those obtained in historical controls with high-dose melphalan followed by a single ASCT. Therefore, considering even the greater complexity of administration of the BU/CY regimen compared with that of single-agent melphalan, we believe the latter should remain the conditioning regimen of choice for ASCT in MM.

Original languageEnglish (US)
Pages (from-to)157-161
Number of pages5
JournalBone Marrow Transplantation
Issue number3
StatePublished - 2009

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation


Dive into the research topics of 'BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this